Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1/2 7Phase 1 6Phase NA 3Phase 3 2Phase EARLY_PHASE1 1

Status

Completed 12Active not recruiting 7Recruiting 5Terminated 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2

Interventions

Cisplatin 62Carboplatin 52Paclitaxel 49Radiotherapy 47Docetaxel 42Gemcitabine 38Cyclophosphamide 36Rituximab 33Capecitabine 28Fluorouracil 27Dexamethasone 27Doxorubicin 26Prednisone 21Bevacizumab 20Pemetrexed 19Oxaliplatin 18Leucovorin 18pembrolizumab 17Vincristine 17Etoposide 17Cytarabine 15Imatinib Mesylate 14Drug Therapy 14Irinotecan 13Filgrastim 13Zoledronic Acid 12Trastuzumab 12Radiosurgery 12Erlotinib Hydrochloride 12Goserelin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Terminated × dexamethasone acetate × Clear all
NCT03151811 2024-01-30

OCEAN

Oncopeptides AB

Phase 3 Terminated
495 enrolled 15 charts
Plasma cell

Multiple Myeloma

NCT00574080 2017-11-20

UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide

University of Arkansas

Phase 3 Terminated
20 enrolled 7 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡